A phase I study of volasertib combined with afatinib, in advanced solid tumors

Authors:

Abstract
To determine the maximum tolerated dose (MTD) of volasertib, a Polo-like kinase inhibitor, combined with afatinib, an oral irreversible ErbB family blocker, in patients with advanced solid tumors (NCT01206816; Study 1230.20).

This publication has 24 references indexed in Scilit: